Β-globin restored autologous hematopoietic stem cells is named as a drug or biological intervention in 3 clinical trials in our China trial register, 3 of which are recruiting. The lead sponsor is Shenzhen Hemogen. Registered phase: Phase EARLY_PHASE1. Conditions studied include β-thalassemia; α-thalassemia.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT05745532 | Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major Patients (ClinicalTrials.gov ↗) β-thalassemia |
Phase EARLY_PHASE1 | Recruiting |
| NCT05851105 | the Safety and Efficacy Evaluation of HGI-002 Injection in Patients With Transfusion-Dependent α-Thalassemia (ClinicalTrials.gov ↗) α-thalassemia |
Phase EARLY_PHASE1 | Recruiting |
| NCT05864170 | the Safety and Efficacy Evaluation of HGI-001 Injection in Patients With Transfusion-Dependent β-Thalassemia (ClinicalTrials.gov ↗) β-thalassemia |
Phase EARLY_PHASE1 | Recruiting |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| β-thalassemia | 2 |
| α-thalassemia | 1 |
| Lead sponsor | Trials |
|---|---|
| Shenzhen Hemogen | 3 |
| Register | Β-globin restored autologous hematopoietic stem cells trials |
|---|---|
| Clinical trials in China | 3 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Β-globin restored autologous hematopoietic stem cells works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Β-globin restored autologous hematopoietic stem cells (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.